A Clinical Trial of Soluble Fiber for Asthma

Recruiting now · Phase 2

Conditions studied: Asthma in Children

In brief

Randomized controlled trial of soluble fiber (Fruitafit Inulin). Participants will complete an ASA 24 dietary recall questionnaire to access their fiber intake. If eligible for the study, participants will be supplemented to their target fiber dosage with either soluble fiber (Fruitafit Inulin) or placebo. Collection of blood serum, fecal samples, and nasal wash will aid in analyzing the microbes present in one's gut and how fiber and diet may impact it. Thus, allowing researchers to better understand the pathways that may connect diet and asthma and if it is possible to improve asthma by altering one's diet.

Key facts

Study ID

NCT06372249

Run by

Phoenix Children's Hospital

People needed

105

Starts

2025-11-10

Expected to finish

2027-05-31

Last updated by the study team

2026-03-04

Who can join

Age: 6 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Between ages 6-17
• Asthma diagnosis within the last 2 years
• Fractional excretion of exhaled nitric oxide (FeNO) > 50 ppb OR a clinical history of environmental allergies as defined by a positive skin prick or positive specific immunoglobulin E (IgE) tests to aeroallergens
• No emergency department visits in the past 1 month
• Ability to consume a liquid drink of fiber or placebo
• Ability to return for a 4-6 week follow-up visit
• No special or unique diet

You may not qualify if…

• Cystic fibrosis
• Bronchiectasis
• Change in asthma medicines other than short acting bronchodilators planned over the next 4-6 weeks
• Baseline estimated daily fiber intake less than or equal to 16 grams as determined by the ASA 24
• Sibling of a participant already enrolled in the study

Where it is running

• Phoenix Children's — Phoenix, Arizona, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.